Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665163 | 1.00 | TDP1 (0.48) | TDP1MAPTEGFRCA12CA1 | |
| SCHEMBL10148075 | 0.92 | EGFR (0.48) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL664060 | 0.90 | MAPT (0.45) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL664061 | 0.90 | MAPT (0.45) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL10148066 | 0.90 | MAPT (0.45) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL664110 | 0.89 | MEN1 (0.46) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL662787 | 0.89 | ADORA3 (0.44) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL662786 | 0.89 | ADORA3 (0.44) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL664109 | 0.89 | MEN1 (0.46) | TDP1MAPTEGFRCCR8LTA4H | |
| SCHEMBL10148190 | 0.85 | ALDH1A1 (0.45) | TDP1MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | TDP1 2744/4885MAPT 2628/4885EGFR 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.